Top Doctor at University of Hong Kong Suggests Aggressively Treat COVID-19 Patients Early with Antiviral Cocktail Medications

Oct 19, 2020 | Antiviral, Chinese University of Hong Kong, COVID-19, Interferon, News, Popular Posts

Top Doctor at University of Hong Kong Suggests Aggressively Treat COVID-19 Patients Early with Antiviral Cocktail Medications

Hong Kong’s medical community knows something about coronaviruses given its experience with the first SARS 17 years ago and of course the most recent SARS-CoV-2 pandemic. The top pandemic doctor there, Yeun Kowk-Yung from University of Hong Kong, suggests a path forward to keep COVID-19 patients out of intensive care, where the probability of death rises significantly. Stop them from entering in the first place by taking far more proactive measures once an individual is in fact infected with SARS-CoV-2. This top doctor emphasizes early and aggressive hospitalization and treatment in a bid to minimize disease escalation and mortality. His approach may be working as, according to a recent Bloomberg report, the COVID-19 death rate in Hong Kong at 2% is well below the worldwide average.

TrialSite breaks down this recent information originating from a Bloomberg journalist Jason Gale.

How is Dr. Kwok-Yung’s approach different to those in Britain or the United States?

Dr. Kwok-Yung shared for Bloomberg, “In places like the U.K. or U.S., usually if you have mild symptoms, you are not admitted to a hospital at all—you just wait at home until you feel very bad or you have shortness of breath.” This is quite different than approach they are taking in Hong Kong reported Mr. Gale where they admit most people test positive so they can be treated immediately and aggressively.

Why do they take this aggressive approach in Hong Kong?

Well the top infectious disease provider shared that first and foremost the transmission of the coronavirus is greatly reduced in the community. Yes, it may seem more draconian that mild COVID-19 cases are hospitalized and isolated but it’s certainly made a difference in the total volume of cases and death rates.

Moreover, with the huge number of clinical trials with potential treatments the number of hospitalized patients affords a chance for more robust matching of patients to clinical trials. Patients can receive targeted advanced investigational treatments immediately as the infections start to worsen.

Why is this important?

According to Yuen, writes Bloomberg’s Gale, the amount of SARS-CoV-2 virus or “viral load” accumulating in patients peaks at this point the time symptoms appear.

What are some treatments the Hong Kong team use?

Although recently shown not effective, the University of Hong Kong suggests that use of the antivirals ribavirin and Kaletra (lopinavir/ritonavir) can work. Yuen suggests that he wasn’t surprised by the recent World Health Organization findings because the drug’s were not given right upon infection onset.

Yuen told Bloomberg, “We know that one drug is not good because all of these are very modestly active.” Continuing he suggested “We need early cocktail therapy to get good results.” Hence the combination of ribavirin, Kaletra and interferon to COVID-19 patients in the first week of disease onset actually reduces the duration of the illness by six days and shortens the hospitalization period by a week based on a study back in May.

Interferon Evidence

Interferon, part of the Hong Kong cocktail, evidences potential efficacy against COVID-19. In fact Bloomberg reported that based on its interview with the Hong Kong top doctor the early use of interferon, at least in some patients, may help combat the virus and reduce death rates. For example, recent clinical trials published in journal Science reveal that approximately 14% of patients with critical SARS-CoV-2 infections actually have inadequate levels of interferon, which is required for immune system defense against viral pathogens. TrialSite has chronicled a few studies suggesting the importance of interferon as a potential treatment.

Lead Research/Investigator

Yuen Kwok-Yung, the Henry Folk professor in infectious diseases, University of Hong Kong; a graduate from University of Hong Kong since 1981 is actually a microbiologist, surgeon and physician and according to Mr. Gale he ”has been at the forefront of the city’s response to infectious outbreaks for decades.”

Call to Action: Follow the link to read Mr. Gale’s piece in Bloomberg in its entirety.

Source: Bloomberg


  1. Ron Carson

    Why not treat at home immediately upon symptoms with ivermectin, zinc and doxycycline? Or, Hydroxychloroquine in lieu of ivermectin. If used within a few days these are almost 100% effective. This has been proven repeatedly. It’s pretty ridiculous at this point.

    • Mike

      Yes, start treatment at the onset of symptoms but use both Hydroxychloroquine with zinc and Ivermectin. The Hydroxychloroquine gets the zinc into the cell nucleus to kill the virus and the Ivermectin kill the virus outside of the cell nucleus. If the disease progresses with lung inflammation then take the inhaled asthma steroid Budesonide. See:

      The second White Coat Summit was held in Washington D.C. October 16-17, 2020

      Masks can not stop any virus. Mask wearing is just political propaganda started by the Chi-Coms.
      Hydroxychloroquine + Zinc + Antibiotics does stop corona virus. For severe corona virus infection you need steroids not ventilators. Ventilators will blow your lungs out an kill you.

      This doctor treats corona virus remotely by prescribing for corona virus at the onset of symptoms for free in all states.

      • ML

        Masks can indeed greatly reduce one’s chances of becoming ill and spreading illness. Inoculum is important, Mike. The more viral load one gets, the more severely ill one can become. So please don’t downplay masks and face coverings. By the way, the MATH+protocol of Dr. Paul Marik has taken HCQ off its list of recommendations. It can be successful in prophylaxis most likely and in extremely early disease, but it really has no place in hospitalized patients who are generally well into or past the viremic phase. Ivermectin however, seems to work in nearly all stages of disease. Couple it with doxy and zinc and you’ve got a winning triple therapy. Please refrain from using terms like “Chi-Coms”- it isn’t helpful, it isn’t kind, and your charge that masks are Chinese “propaganda,” isn’t even true. I wish Americans were smarter.

        • Sandi

          Well said, ML!

    • Debra Sewell

      Ron. I’m not a doctor. Just a person who took an interest in ivermectin since April 2020. As it became more and more successful I’ve tried to tell people but no one listens. My sister in Costa Rica listened. When she came to the US in late Sept. she brought Ivermectin, doxycycline, and zinc with her. One day when she felt a sore throat and body aches she gave her self a treatment. I brought it up to a doctor I saw at Kaiser who yelled at me that ivermectin was no good! I didn’t believe him. Ironic as I was there for heart palpitations which is a side effect of remdisivir but not ivermectin. P

    • Suzanne L Adams, CT (ASCP)

      Good point! More doctors need to stand up and make sure people know that they’re the only ones with licenses to prescribe medications even off label, and they should do diligence to do so when they see fit. Many doctors have “oppositional defiance disorder” against anything natural and this is because they have been brainwashed by big Pharma to think that anything natural has no medicinal power. Since when? The average allopathic physician has very little education in biochemistry which is nutrition. I know as I married a medical student and watched and helped him go through all of his training to become a board-certified pediatric critical care physician. He absolutely had no courses in nutrition. One reason he chose critical care was because hyperalimentation was involved.

  2. job roos

    question: Am I cursing in the church when I note that the Raoult ,Zelenko and Borody protocols are missing in the article . while they support the same strategy for nearly half a year ,with great results.Are hydroxychloroquin and zinc and Ivermectin still tabu?

    • Anna

      It’s terrible to watch people die who could have been saved! Early treatment is the answer, but the people who could put this approach in place is nowhere to be seen and heard! Doctors speak up, but they are barred from the main stream. Elens (The Netherlands) Zelenko and Perron (France) In Australia they saw early treatment as the best answer.

  3. John

    It is noteworthy indeed that Professor YUEN is suggesting that physicians should direct focus on prevention of the progression of COVID-19 with the early administration of anti virals. There seems to be an increasing body of evidence that SARS COV-2 can lead to over stimulation of the immune response which is the ultimate killer. With the current SoC, we send patients home to wait out to virus, then try to recover from whatever situation has developed in the patient if they develop at all.

    Notwithstanding the documented potential of Ivermectin, we should all hope that Dr. YUEN proves to be right. It would be a shame for all of these advanced anti-viral drugs to go to waste without a fair shot at proving their effectiveness.

    • TrialSite

      Dear John,
      Thanks as always for your visit and contribution. TrialSite”s overall point of view aligns. There is growing evidence that more proactive care needs to occur upfront. We think the U.S. research establishment understands this hence why the growing number of studies involving monoclonal antibodies for example that are used to treat even an individual that merely came into contact with someone with a positive COVID-19 test result. An example of such a study would be the Regeneron Study (NCT044523818) titled “Study Assessing the Efficacy and Safety of ANti-Spike SARS-CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults Who are Household Contacts to an Individual with a Positive SARS-CoV-2 RT-PCR Assay.” See the link:

      So in the United States there is a growing recognition of this need however it would appear that the emphasis is on highly novel investigational bio-pharmaceutical experimental products. Which by the way we think are needed (apparently they helped POTUS) so we at TrialSite support the important work of Regeneron, Lilly and others.

      We also think there needs to be public subsidy of other approaches occurring around the world. For example, we have sent an email communication to the head of the NIH suggesting there should as well be a focus on existing therapies that others’ are testing around the world–ones that are already FDA approved, economical and available.

      Here at TrialSite we don’t buy into the classical fallacy of the “false dilemma:” that is it’s either advanced biopharmaceuticals or nothing which is basically what we have today in the United States. This is perhaps one of the reasons why we have experienced so much death in this great country–an incredible tragedy. We wait until it’s too late and with the level of people with comorbidity challenges we face an exponential problem.

      Unless people start using critical thinking to activate, collaborate, and collectively speak up we are headed down a path that won’t be optimal for all. Hence the importance of TrialSite as an independent platform to discuss these urgently important matters.


  4. Gerard Byrne

    So what is the delay in authorizing the Regeneron cocktail? I know the trial results were from a small population but the results “were compelling”, said the Regeneron officials. The fact that the President received it says there is consensus among Dr’s.

    • TrialSite

      Dear Gerard,
      There is certainly some data points out there that the REGN-COV2 appears to work but is there evidence? That requires comprehensive data sets from the clinical programs they are running. Now to your point they have submitted a request to FDA for emergency use authorization and that could be approved soon. That’s not a full approval but it is an authorization for use during the pandemic. And as we saw with remdesivir it can lead to approval. At TrialSite we were skeptical about some of how the REGN-COV2 program got started but we have heard from multiple sources that there seems to be promising data and we can attest that the company has been incredibly transparent with us. Any time we shoot them over a critical question they respond the same day. We can’t say that about all other companies. We have been impressed with Regeneron although we are a small media company and clearly only have a point of view. But overall looks promising.

Pin It on Pinterest